These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 20663130)

  • 1. Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial.
    Chen Z; Wu J; Zhang Y; Wei J; Leng X; Bi J; Li R; Yan L; Quan Z; Chen X; Yu Y; Wu Z; Liu D; Ma X; Maroko R; Cooper A
    BMC Infect Dis; 2010 Jul; 10():217. PubMed ID: 20663130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].
    Oliva ME; Rekha A; Yellin A; Pasternak J; Campos M; Rose GM; Babinchak T; Ellis-Grosse EJ; Loh E;
    BMC Infect Dis; 2005 Oct; 5():88. PubMed ID: 16236177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.
    Babinchak T; Ellis-Grosse E; Dartois N; Rose GM; Loh E; ;
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S354-67. PubMed ID: 16080073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience.
    Fomin P; Koalov S; Cooper A; Babinchak T; Dartois N; De Vane N; Castaing N; Tellado J;
    J Chemother; 2008 Oct; 20 Suppl 1():12-9. PubMed ID: 19036670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.
    Ramirez J; Dartois N; Gandjini H; Yan JL; Korth-Bradley J; McGovern PC
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1756-62. PubMed ID: 23357775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.
    Freire AT; Melnyk V; Kim MJ; Datsenko O; Dzyublik O; Glumcher F; Chuang YC; Maroko RT; Dukart G; Cooper CA; Korth-Bradley JM; Dartois N; Gandjini H;
    Diagn Microbiol Infect Dis; 2010 Oct; 68(2):140-51. PubMed ID: 20846586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China.
    Chen Y; Zhu D; Zhang Y; Zhao Y; Chen G; Li P; Xu L; Yan P; Hickman MA; Xu X; Tawadrous M; Wible M
    Ther Clin Risk Manag; 2018; 14():2327-2339. PubMed ID: 30584308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin.
    Mallick R; Sun S; Schell SR
    Surg Infect (Larchmt); 2007 Apr; 8(2):159-72. PubMed ID: 17437361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
    Fabian TC; File TM; Embil JM; Krige JE; Klein S; Rose A; Melnick D; Soto NE
    Surg Infect (Larchmt); 2005; 6(3):269-82. PubMed ID: 16201937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study.
    Kohno S; Bando H; Yoneyama F; Kikukawa H; Kawahara K; Shirakawa M; Aoyama N; Brown M; Paschke A; Takase A
    J Infect Chemother; 2021 Feb; 27(2):262-270. PubMed ID: 33191112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
    Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
    Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.
    Eklund AE; Nord CE
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():79-85. PubMed ID: 8383657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial.
    Solomkin J; Evans D; Slepavicius A; Lee P; Marsh A; Tsai L; Sutcliffe JA; Horn P
    JAMA Surg; 2017 Mar; 152(3):224-232. PubMed ID: 27851857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
    Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A
    J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tigecycline.
    Frampton JE; Curran MP
    Drugs; 2005; 65(18):2623-35; discussion 2636-7. PubMed ID: 16392879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
    Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
    J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of intravenous doripenem in patients with acute biliary tract infection: a multicenter, randomized, controlled trial with imipenem/cilastatin as comparator.
    Tazuma S; Igarashi Y; Inui K; Ohara H; Tsuyuguchi T; Ryozawa S;
    J Gastroenterol; 2015 Feb; 50(2):221-9. PubMed ID: 24795092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus.
    Embil JM; Soto NE; Melnick DA
    Clin Ther; 2006 Aug; 28(8):1164-1174. PubMed ID: 16982293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections.
    Brismar B; Malmborg AS; Tunevall G; Wretlind B; Bergman L; Mentzing LO; Nyström PO; Kihlström E; Bäckstrand B; Skau T
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2766-73. PubMed ID: 1336347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.